Literature DB >> 15947545

The promising future of proteomics in cancer diagnosis and treatment.

Kevin M Friedman1, Bernard A Fox.   

Abstract

Cancer is a leading cause of death in developed countries. For most cancers, a patient's prognosis improves dramatically when the disease is detected at an early stage. Although advancements in imaging technology have dramatically improved early detection, many cancers go undetected until it is too late. As cancer develops, molecular changes occur before many of the current prognostic markers can be detected. Proteomics will be used to interrogate the protein milieu in serum and urine to detect molecular changes indicative of a disease state and will provide a cost-effective alternative to current diagnostic tools.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947545     DOI: 10.1097/00042737-200507000-00002

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  2 in total

1.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

2.  Down-regulation of beta-centractin might be involved in dendritic cells dysfunction and subsequent hepatocellular carcinoma immune escape: a proteomic study.

Authors:  Yong-Qiang Weng; Shuang-Jian Qiu; Yin-Kun Liu; Jia Fan; Qiang Gao; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-07       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.